Autologous stem cell transplantation for relapsed/refractory diffuse large B-cell lymphoma: efficacy in the rituximab era and comparison to first allogeneic transplants. A report from the EBMT Lymphoma Working Party

S. P. Robinson, A. Boumendil, H. Finel, D. Blaise, X. Poire, E. Nicolas-Virelizier, R. Or, R. Malladi, A. Corby, L. Fornecker, D. Caballero, D. Pohlreich, A. Nagler, C. Thieblemont, J. Finke, E. Bachy, L. Vincent, W. Schroyens, H. Schouten, P. Dreger

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)365-371
JournalBone Marrow Transplantation
Volume51
Issue number3
DOIs
Publication statusPublished - Mar 2016

Cite this

Robinson, S. P., Boumendil, A., Finel, H., Blaise, D., Poire, X., Nicolas-Virelizier, E., Or, R., Malladi, R., Corby, A., Fornecker, L., Caballero, D., Pohlreich, D., Nagler, A., Thieblemont, C., Finke, J., Bachy, E., Vincent, L., Schroyens, W., Schouten, H., & Dreger, P. (2016). Autologous stem cell transplantation for relapsed/refractory diffuse large B-cell lymphoma: efficacy in the rituximab era and comparison to first allogeneic transplants. A report from the EBMT Lymphoma Working Party. Bone Marrow Transplantation, 51(3), 365-371. https://doi.org/10.1038/bmt.2015.286